96 related articles for article (PubMed ID: 16257848)
1. Investigations of clofibrate in alternative carcinogenicity models.
Santostefano MJ; Hoivik DJ; Miller RT
Int J Toxicol; 2005; 24(5):285-8. PubMed ID: 16257848
[No Abstract] [Full Text] [Related]
2. Evaluation of the carcinogenic potential of clofibrate in the rasH2 mouse.
Nesfield SR; Clarke CJ; Hoivik DJ; Miller RT; Allen JS; Selinger K; Santostefano MJ
Int J Toxicol; 2005; 24(5):301-11. PubMed ID: 16257850
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the carcinogenic potential of clofibrate in the FVB/Tg.AC mouse after oral administration--part I.
Torrey CE; Wall HG; Campbell JA; Kwanyuen P; Hoivik DJ; Miller RT; Allen JS; Jayo MJ; Selinger K; Savina PM; Santostefano MJ
Int J Toxicol; 2005; 24(5):313-25. PubMed ID: 16257851
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the carcinogenic potential of clofibrate in the neonatal mouse.
Nesfield SR; Williams TC; Hoivik DJ; Miller RT; Allen JS; Selinger K; Rickert D; Santostefano MJ
Int J Toxicol; 2005; 24(5):341-8. PubMed ID: 16257853
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the carcinogenic potential of clofibrate in the p53+/- mouse.
Torrey CE; Campbell JA; Hoivik DJ; Miller RT; Allen JS; Mann PC; Selinger K; Rickert D; Savina PM; Santostefano MJ
Int J Toxicol; 2005; 24(5):289-99. PubMed ID: 16257849
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the carcinogenic potential of clofibrate in the FVB/Tg.AC mouse after dermal application--part II.
Torrey CE; Wall HG; Campbell JA; Kwanyuen P; Hoivik DJ; Miller RT; Allen JS; Jayo MJ; Selinger K; Santostefano MJ
Int J Toxicol; 2005; 24(5):327-39. PubMed ID: 16257852
[TBL] [Abstract][Full Text] [Related]
7. Genetically altered mouse models for identifying carcinogens.
Tennant RW; Stasiewicz S; Mennear J; French JE; Spalding JW
IARC Sci Publ; 1999; (146):123-50. PubMed ID: 10353386
[No Abstract] [Full Text] [Related]
8. Use of genetically modified mouse models for evaluation of carcinogenic risk: considerations for the laboratory animal scientist.
Recio L; Everitt J
Comp Med; 2001 Oct; 51(5):399-405. PubMed ID: 11924798
[TBL] [Abstract][Full Text] [Related]
9. Hepatic drug metabolizing enzymes induced by clofibrate in rasH2 mice.
Katsutani N; Sekido T; Aoki T; Sagami F
Toxicol Lett; 2000 Jun; 115(3):223-9. PubMed ID: 10814892
[TBL] [Abstract][Full Text] [Related]
10. Transcription profiling distinguishes dose-dependent effects in the livers of rats treated with clofibrate.
Kramer JA; Blomme EA; Bunch RT; Davila JC; Jackson CJ; Jones PF; Kolaja KL; Curtiss SW
Toxicol Pathol; 2003; 31(4):417-31. PubMed ID: 12851107
[TBL] [Abstract][Full Text] [Related]
11. The transgenic mouse assay as an alternative test method for regulatory carcinogenicity studies--implications for REACH.
Wells MY; Williams ES
Regul Toxicol Pharmacol; 2009 Mar; 53(2):150-5. PubMed ID: 19126422
[TBL] [Abstract][Full Text] [Related]
12. Studies evaluating the utility of N-methyl-N-nitrosourea as a positive control in carcinogenicity studies in the p53+/- mouse.
Hoivik DJ; Allen JS; Wall HG; Nold JB; Miller RT; Santostefano MJ
Int J Toxicol; 2005; 24(5):349-56. PubMed ID: 16257854
[TBL] [Abstract][Full Text] [Related]
13. [The use of biotechnological recombinant-mice in biological safety research].
Inoue T
Eisei Shikenjo Hokoku; 1996; (114):1-12. PubMed ID: 9037857
[TBL] [Abstract][Full Text] [Related]
14. Alternative mouse models for carcinogenicity assessment: industry use and issues with pathology interpretation.
Long GG; Morton D; Peters T; Short B; Skydsgaard M
Toxicol Pathol; 2010 Jan; 38(1):43-50. PubMed ID: 19915137
[TBL] [Abstract][Full Text] [Related]
15. [Usefulness of transgenic mice in carcinogenicity tests].
Hayashi Y; Kodama Y; Fuji S
Jikken Dobutsu; 1993 Jul; 42(3):282-6. PubMed ID: 8354349
[No Abstract] [Full Text] [Related]
16. Long- and medium-term carcinogenicity studies in animals and short-term genotoxicity tests.
Feron VJ; Schwarz M; Hemminki K; Krewski D
IARC Sci Publ; 1999; (131):103-29. PubMed ID: 10505295
[No Abstract] [Full Text] [Related]
17. The utility of the K6/ODC transgenic mouse as an alternative short term dermal model for carcinogenicity testing of pharmaceuticals.
Miller TJ; Honchel R; Espandiari P; Knapton A; Zhang J; Sistare FD; Hanig JP
Regul Toxicol Pharmacol; 2008 Feb; 50(1):87-97. PubMed ID: 18069108
[TBL] [Abstract][Full Text] [Related]
18. Consideration of short-term carcinogenicity tests using transgenic mouse models.
Blain PG; Battershill JM; Venitt S; Cooper CC; Fielder RJ
Mutat Res; 1998 Jul; 403(1-2):259-63. PubMed ID: 9726026
[No Abstract] [Full Text] [Related]
19. Panel discussion: alternative mouse models for carcinogenicity assessment.
French JE; Leblanc B; Long GG; Morton D; Storer R; Leighton J; Swenberg J; Tsuda H
Toxicol Pathol; 2010 Jan; 38(1):72-5. PubMed ID: 19884653
[TBL] [Abstract][Full Text] [Related]
20. The use of genetically modified animals in carcinogenicity bioassays.
Maronpot RR
Toxicol Pathol; 2000; 28(3):450-3. PubMed ID: 10862565
[No Abstract] [Full Text] [Related]
[Next] [New Search]
